Publications

Cost-effectiveness of routine versus indicated antibiotic therapy in the management of severe wasting in children.

Abstract

BACKGROUND: In the outpatient management of severe wasting, routine antibiotic therapy is recommended for all children upon admission regardless of whether clinical signs of infection are present.

Isanaka S Tang K Berthé F Grais RF Pandya A
Cost effectiveness and resource allocation : C/E 2022 Aug 03; 20(1); . doi: 10.1186/s12962-022-00374-z. Epub 2022 08 03
Antibiotic therapy Cost-effectiveness Niger Severe acute malnutrition Wasting

Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.

Abstract

BACKGROUND: Many countries are now replacing non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line antiretroviral therapy (ART) with a regimen containing tenofovir disoproxil fumarate, lamivudine, and dolutegravir (TL

Schramm B Temfack E Descamps D Nicholas S Peytavin G Bitilinyu-Bangoh JE Storto A Lê MP Abdi B Ousley J Kalua T Calvez V Jahn A Marcelin AG Szumilin E
The lancet. HIV 2022 Aug ; 9(8); . doi: 10.1016/S2352-3018(22)00136-9. Epub 2022 07 29

Burden and risk factors for relapse following successful treatment of uncomplicated severe acute malnutrition in young children: Secondary analysis from a randomised trial in Niger.

Abstract

This study aimed to quantify the burden of relapse following successful treatment for uncomplicated severe acute malnutrition (SAM) and to identify associated risk factors in rural Niger.

Bliznashka L Grantz KH Botton J Berthé F Garba S Hanson KE Grais RF Isanaka S
Maternal & child nutrition 2022 Jul 21; . doi: 10.1111/mcn.13400. Epub 2022 07 21
Niger community-based management of acute malnutrition discharge hospitalisation relapse severe acute malnutrition wasting
Ratnayake R Peyraud N Ciglenecki I Gignoux E Lightowler M Azman AS Gakima P Ouamba JP Sagara JA Ndombe R Mimbu N Ascorra A Welo PO Mukamba Musenga E Miwanda B Boum Y Checchi F Edmunds WJ Luquero F Porten K Finger F
BMJ open 2022 07 06; 12(7); . doi: 10.1136/bmjopen-2022-061206. Epub 2022 07 06
epidemiology geographical mapping infection control public health

Gender equity in health research publishing in Africa.

Abstract

INTRODUCTION: Women researchers find it more difficult to publish in academic journals than men, an inequity that affects women's careers and was exacerbated during the pandemic, particularly for women in low-income and middle-income c

Baobeid A Faghani-Hamadani T Sauer S Boum Y Hedt-Gauthier BL Neufeld N Odhiambo J Volmink J Shuchman M Di Ruggiero E Condo JU
BMJ global health 2022 Jul ; 7(7); . doi: 10.1136/bmjgh-2022-008821. Epub 2022 07 14
Public Health

Capacity Building in Sub-Saharan Africa as Part of the INTENSE-TBM Project During the COVID-19 Pandemic.

Abstract

Tuberculous meningitis (TBM) is the most severe and disabling form of tuberculosis (TB), with at least 100,000 cases per year and a mortality rate of up to 50% in individuals co-infected with human immunodeficiency virus type 1 (HIV-1).

Ariza-Vioque E Ello F Andriamamonjisoa H Machault V González-Martín J Calvo-Cortés MC Eholié S Tchabert GA Ouassa T Raberahona M Rakotoarivelo R Razafindrakoto H Rahajamanana L Wilkinson RJ Davis A Maxebengula M Abrahams F Muzoora C Nakigozi N Nyehangane D Nanjebe D Mbega H Kaitano R Bonnet M Debeaudrap P Miró JM Anglaret X Rakotosamimanana N Calmy A Bonnet F Ambrosioni J
Infectious diseases and therapy 2022 Jun 29; . doi: 10.1007/s40121-022-00667-z. Epub 2022 06 29
Africa Capacity building Clinical research HIV INTENSE-TBM Tuberculous meningitis

Integrating hepatitis C treatment into multidrug-resistant TB care.

Abstract

BACKGROUND: Direct-acting antivirals (DAAs) are not widely used for patients with chronic hepatitis C virus (HCV) infection and multidrug- or rifampicin-resistant TB (MDR/RR-TB).

Kirakosyan O Melikyan N Falcao J Khachatryan N Atshemyan H Oganezova I Aznauryan A Yeghiazaryan L Sargsyants N Hayrapetyan A Balkan S Hewison C Huerga H
Public health action 2022 Jun 21; 12(2); . doi: 10.5588/pha.22.0002. Epub 2022 06 23
DAAs HCV MDRTB direct-acting antivirals integrated care